Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 21

1558P - Preoperative pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma (ESCC): The phase II Keystone-001 trial

Date

21 Oct 2023

Session

Poster session 21

Topics

Tumour Site

Oesophageal Cancer

Presenters

hongjing jiang

Citation

Annals of Oncology (2023) 34 (suppl_2): S852-S886. 10.1016/S0923-7534(23)01930-0

Authors

H. jiang1, X. Shang2, Y. Xie3, G. Zhao4, C. Zhang5, W. Zhang6, L. Liu7, R. Li8, J. Yue5, C. Chen5, X. Duan5, Z. Ma5, Y. Sun4, J. Yu6, X. Ren9

Author affiliations

  • 1 Esophageal Invasive Surgery Department, Tianjin Medical University Cancer Institute & Hospital, 300011 - Tianjin/CN
  • 2 Department Of Minimally Invasive Esophageal Surgery, Tianjin Medical University Cancer Institute & Hospital, 300011 - Tianjin/CN
  • 3 Department Of Pancreatic Cancer, TMUCIH - Tianjin Medical University Cancer Institute and Hospital, 300060 - Tianjin/CN
  • 4 Department Of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN
  • 5 Department Of Minimally Invasive Esophageal Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN
  • 6 Department Of Immune Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN
  • 7 Department Of Immune Oncology, TMUCIH - Tianjin Medical University Cancer Institute and Hospital, 300060 - Tianjin/CN
  • 8 Department Of Immune Oncology, Tianjin Medical University Cancer Institute and Hospital, 300060 - Tianjin/CN
  • 9 Department Of Immune Oncology, Tianjin Cancer Hospital, 300060 - Tianjin/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1558P

Background

The Keystone-001 study was designed to prospectively evaluate the efficacy and safety of preoperative treatment with pembrolizumab plus paclitaxel and cisplatin followed by Da Vinci robotic radical surgery in patients with locally advanced (stage III) ESCC. The study also explored the potential mechanism of this treatment strategy (NCT 04389177, 5/15/2020).

Methods

The full study methods for this prospective, single-arm, single-center, open-label, phase-II study have been published previously. For further investigating the immune cell subpopulations that determine the efficacy, we performed single-cell sequencing on peripheral blood and tumor tissues after neoadjuvant therapy, and validated using flow cytometry.

Results

Of the 49 patients enrolled between July 8, 2020, and February 10, 2022, 47 received neoadjuvant therapy and were included in the ITT analysis. Among all patients who received neoadjuvant therapy, no grade ≥3 AEs were reported. Improvements from baseline nutritional status were observed with increases in patients’ median body weight and NRI. QoL evaluations showed improvements from baseline to post-adjuvant therapy in all functional scales and symptom scales of EORTC QLQ-C30 and in all items of the EORTC QLQ-OES18 questionnaire. Among all 45 patients in the efficacy analysis, the MPR rate was 73.3%, the pCR rate was 42.2%, the ORR was 95.6%, and the DCR was 100%. After a median follow-up of 23.3 months (95% CI 20.6, 24.9; maximum follow-up 34 months), the 1- and 2-year OS and DFS rates were 95.6 and 90.5% and 95.6 and 86.3%, respectively. The single-cell sequencing results showed that the main cell populations that affect the response of this treatment strategy were NKT and NK cell subpopulations in peripheral blood. Further analysis results showed that the TRGC2+NKT and FGFBP2+NK cell subpopulation in peripheral blood were more significantly increased in peripheral blood from patients with a good response.

Conclusions

The preliminary findings of this trial were safe and effective, and further phase III studies (Keystone-002) have begun to recruit participants.

Clinical trial identification

NCT 04389177.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Tianjin Science and Technology Bureau, Beijing Xisike Clinical Oncology Foundation.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.